[Fotemustine: muphoran].
Avril
M-F
MF
Service de Dermatologie, Hôpital Cochin, AP-HP et Institut Cochin, Inserm U 567, CNRS (UMR 8104), Université Paris V-René Descartes, Paris. marie-francoise.avril@cch.aphp.fr
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine